Immunological mechanisms in drug-induced liver injury

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Immune-mediated injury plays a primary or secondary role in many forms of drug-induced liver injury (DILI) (1,2). This mechanism of DILI is suggested clinically by the presence of features of systemic immune activation such as concomitant fever, rash, atypical lymphocytes, and/or eosinophilia. When drug rechallenge occurs, immune-mediated mechanisms of DILI are confirmed by the development of an accelerated onset of equally or more severe liver injury indicating the presence of immunological memory, the signature of an adaptive immune response (1,3). In many such cases, hepatic drug metabolism has been found to produce reactive metabolites that haptenate or alkylate self proteins which in turn elicit adaptive immune responses and associated liver injury in genetically susceptible individuals (2,4-6). More recently, it has been recognized that drugs that directly injure hepatocytes may also trigger innate immune responses apparently directed at damaged hepatocytes (2,7,8).

Original languageEnglish (US)
Title of host publicationDrug-Induced Liver Disease, Second Edition
PublisherCRC Press
Pages115-123
Number of pages9
ISBN (Electronic)9781420021141
ISBN (Print)9780849398964
StatePublished - Jan 1 2007

Fingerprint

Chemical and Drug Induced Liver Injury
Adaptive Immunity
Hepatocytes
Liver
Wounds and Injuries
Pharmaceutical Preparations
Immunologic Memory
Eosinophilia
Exanthema
Innate Immunity
Fever
Lymphocytes
Proteins

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Thiele, D. L. (2007). Immunological mechanisms in drug-induced liver injury. In Drug-Induced Liver Disease, Second Edition (pp. 115-123). CRC Press.

Immunological mechanisms in drug-induced liver injury. / Thiele, Dwain L.

Drug-Induced Liver Disease, Second Edition. CRC Press, 2007. p. 115-123.

Research output: Chapter in Book/Report/Conference proceedingChapter

Thiele, DL 2007, Immunological mechanisms in drug-induced liver injury. in Drug-Induced Liver Disease, Second Edition. CRC Press, pp. 115-123.
Thiele DL. Immunological mechanisms in drug-induced liver injury. In Drug-Induced Liver Disease, Second Edition. CRC Press. 2007. p. 115-123
Thiele, Dwain L. / Immunological mechanisms in drug-induced liver injury. Drug-Induced Liver Disease, Second Edition. CRC Press, 2007. pp. 115-123
@inbook{7738847ce0554c88b86b483a30478a40,
title = "Immunological mechanisms in drug-induced liver injury",
abstract = "Immune-mediated injury plays a primary or secondary role in many forms of drug-induced liver injury (DILI) (1,2). This mechanism of DILI is suggested clinically by the presence of features of systemic immune activation such as concomitant fever, rash, atypical lymphocytes, and/or eosinophilia. When drug rechallenge occurs, immune-mediated mechanisms of DILI are confirmed by the development of an accelerated onset of equally or more severe liver injury indicating the presence of immunological memory, the signature of an adaptive immune response (1,3). In many such cases, hepatic drug metabolism has been found to produce reactive metabolites that haptenate or alkylate self proteins which in turn elicit adaptive immune responses and associated liver injury in genetically susceptible individuals (2,4-6). More recently, it has been recognized that drugs that directly injure hepatocytes may also trigger innate immune responses apparently directed at damaged hepatocytes (2,7,8).",
author = "Thiele, {Dwain L}",
year = "2007",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780849398964",
pages = "115--123",
booktitle = "Drug-Induced Liver Disease, Second Edition",
publisher = "CRC Press",

}

TY - CHAP

T1 - Immunological mechanisms in drug-induced liver injury

AU - Thiele, Dwain L

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Immune-mediated injury plays a primary or secondary role in many forms of drug-induced liver injury (DILI) (1,2). This mechanism of DILI is suggested clinically by the presence of features of systemic immune activation such as concomitant fever, rash, atypical lymphocytes, and/or eosinophilia. When drug rechallenge occurs, immune-mediated mechanisms of DILI are confirmed by the development of an accelerated onset of equally or more severe liver injury indicating the presence of immunological memory, the signature of an adaptive immune response (1,3). In many such cases, hepatic drug metabolism has been found to produce reactive metabolites that haptenate or alkylate self proteins which in turn elicit adaptive immune responses and associated liver injury in genetically susceptible individuals (2,4-6). More recently, it has been recognized that drugs that directly injure hepatocytes may also trigger innate immune responses apparently directed at damaged hepatocytes (2,7,8).

AB - Immune-mediated injury plays a primary or secondary role in many forms of drug-induced liver injury (DILI) (1,2). This mechanism of DILI is suggested clinically by the presence of features of systemic immune activation such as concomitant fever, rash, atypical lymphocytes, and/or eosinophilia. When drug rechallenge occurs, immune-mediated mechanisms of DILI are confirmed by the development of an accelerated onset of equally or more severe liver injury indicating the presence of immunological memory, the signature of an adaptive immune response (1,3). In many such cases, hepatic drug metabolism has been found to produce reactive metabolites that haptenate or alkylate self proteins which in turn elicit adaptive immune responses and associated liver injury in genetically susceptible individuals (2,4-6). More recently, it has been recognized that drugs that directly injure hepatocytes may also trigger innate immune responses apparently directed at damaged hepatocytes (2,7,8).

UR - http://www.scopus.com/inward/record.url?scp=84997933923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997933923&partnerID=8YFLogxK

M3 - Chapter

SN - 9780849398964

SP - 115

EP - 123

BT - Drug-Induced Liver Disease, Second Edition

PB - CRC Press

ER -